| Dr Tatyana O Yetto, MD | |
|
1 Boone Rd, Bremerton, WA 98312-1894 | |
| (619) 532-9660 | |
| Not Available |
| Full Name | Dr Tatyana O Yetto |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Location | 1 Boone Rd, Bremerton, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558657031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 159905 (California) | Secondary |
| 207N00000X | Dermatology | 0101252505 (Virginia) | Primary |
| Entity Name | Dermatology Specialists Of Fort Worth Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417434119 PECOS PAC ID: 4587917117 Enrollment ID: O20181030000722 |
News Archive
Weight training significantly improves the quality of life of women recently treated for breast cancer, according to a new study.
Fredericksburg Oncology is now accepting patients for a new clinical trial supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma. The current trial, designed at the Mayo Clinic, combines chemotherapy with targeted molecular agents in an effort to improve control of this difficult disease, reports Dr. Frederick C. Tucker, Jr., who heads this practice.
Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.
In the evolving global healthcare marketplace, a patient-centric approach has become part of the formula for long-term success in the pharmaceutical sector. Facing declining sales from patent losses and payer pressures, the pharma sector is turning to patient support programs and activities to help drive clinical and commercial success.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tatyana O Yetto, MD 8901 Wisconsin Ave, Bethesda, MD 20889-0001 Ph: () - | Dr Tatyana O Yetto, MD 1 Boone Rd, Bremerton, WA 98312-1894 Ph: (619) 532-9660 |
News Archive
Weight training significantly improves the quality of life of women recently treated for breast cancer, according to a new study.
Fredericksburg Oncology is now accepting patients for a new clinical trial supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma. The current trial, designed at the Mayo Clinic, combines chemotherapy with targeted molecular agents in an effort to improve control of this difficult disease, reports Dr. Frederick C. Tucker, Jr., who heads this practice.
Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.
In the evolving global healthcare marketplace, a patient-centric approach has become part of the formula for long-term success in the pharmaceutical sector. Facing declining sales from patent losses and payer pressures, the pharma sector is turning to patient support programs and activities to help drive clinical and commercial success.
Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period.
› Verified 9 days ago
Jeffrey Wayne Gertner, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1 Boone Rd, Bremerton, WA 98312 Phone: 360-475-4216 Fax: 360-475-4430 | |
Katherine Lynn Brown, MD, MPH Dermatology Medicare: Accepting Medicare Assignments Practice Location: 555 Pacific Ave Ste 202, Bremerton, WA 98337 Phone: 360-782-1700 |